Avodart Cost in Rhode Island 2026: Dutasteride Prices, Insurance, and Savings

What Does Dutasteride Cost Without Insurance in Rhode Island?

Generic dutasteride costs about $25 per month cash-pay at Rhode Island retail pharmacies in 2026, while the brand-name Avodart carries a manufacturer list price near $290 per month. The gap between those two numbers is the single most important pricing fact for any Rhode Island patient filling this prescription out of pocket.

Dutasteride is a dual 5-alpha reductase inhibitor that blocks both type 1 and type 2 isoenzymes, suppressing dihydrotestosterone (DHT) by up to 90% [1]. The FDA approved Avodart for benign prostatic hyperplasia (BPH) in 2001, and multiple generic versions entered the U.S. market after patent expiration, pushing retail prices sharply downward [2]. Because generics carry the same active ingredient at identical strength, the FDA's generic drug program confirms therapeutic equivalence under its Orange Book ratings [3].

At Rhode Island pharmacies, a 30-capsule supply of generic dutasteride 0.5 mg ranges from roughly $18 at warehouse clubs with discount programs to $35 at standard chain pharmacies without a coupon. Adding a free GoodRx or similar coupon card can push the price below $20 at certain Providence-area locations. The AHRQ Medical Expenditure Panel Survey consistently documents that branded drug prices can exceed generic equivalents by 10-fold or more once generics are established [4], and dutasteride fits that pattern precisely.

Patients paying cash should always ask the pharmacist for the generic and confirm the coupon price before the prescription is filled. A one-minute price check can save more than $250 per month.

Does Rhode Island Medicaid Cover Avodart or Dutasteride?

Rhode Island Medicaid (RIte Care and Rhody Health) covers dutasteride for BPH, but the plan requires prior authorization (PA) before dispensing [5]. Generic dutasteride is the covered form; brand Avodart is not separately reimbursed once a generic is available.

The PA process for BPH typically requires documentation of diagnosis, symptom severity (often an AUA Symptom Score of 8 or higher), and confirmation that the prescriber has ruled out prostate cancer as the cause of obstructive symptoms. The American Urological Association guideline on BPH management specifies that 5-alpha reductase inhibitors are appropriate for patients with prostate volumes greater than 30 mL or PSA levels above 1.5 ng/mL [6]. Physicians submitting a PA request should reference those thresholds directly to speed approval.

Off-label use for androgenetic alopecia is less consistently covered. Rhode Island Medicaid formulary documents do not list hair-loss indications as PA-eligible without exceptional clinical justification. A study published in the Journal of the American Academy of Dermatology by Eun et al. (2010, N=153) found that dutasteride 0.5 mg outperformed finasteride 1 mg on hair count at 24 weeks [7], but off-label coverage decisions depend on payer policy rather than trial evidence alone.

Patients denied PA have 90 days to file a grievance under Rhode Island Medicaid managed care rules. The state's External Review Organization can independently review denials, and PA overturns are granted in a meaningful share of cases where clinical documentation is thorough.

Which Private Insurance Plans Cover Dutasteride in Rhode Island?

Most commercial plans in Rhode Island cover generic dutasteride as a Tier 2 or Tier 3 drug for BPH, with copays typically between $10 and $45 per 30-day supply depending on plan design [8].

Blue Cross Blue Shield of Rhode Island, Tufts Health Plan (now Point32Health), and UnitedHealthcare all operate plans in the state's individual and employer markets. Each of those carriers lists generic dutasteride on formulary for BPH. The brand Avodart typically sits at Tier 4 or 5, making its cost-share prohibitive for most members unless a step-therapy or non-preferred brand exception is approved.

The FDA's drug pricing transparency data confirms that insurer formulary placement drives patient out-of-pocket costs more than any other single variable [9]. For a Rhode Island patient on a high-deductible health plan, the generic cash price of $25 per month may actually be lower than the in-network copay before the deductible is met. Patients in that situation can decline to use insurance and pay cash with a discount card instead. Pharmacists are legally able to process a prescription as a cash transaction even when the patient has active insurance.

Step therapy is common for 5-alpha reductase inhibitors. Many plans require a trial of alpha-blockers such as tamsulosin before approving dutasteride. The AUA guideline notes that combination therapy with an alpha-blocker and a 5-alpha reductase inhibitor is appropriate for patients at risk of BPH progression [6], which can support a combination therapy request that bypasses single-agent step therapy.

Is Compounded Dutasteride Legal in Rhode Island?

Yes. Licensed 503A compounding pharmacies in Rhode Island may legally prepare dutasteride capsules for individual patients when a valid prescription exists [10]. The price for compounded dutasteride through a 503A pharmacy in Rhode Island runs approximately $40 per month, higher than generic retail but sometimes chosen for specific dose strengths or combination formulations not available commercially.

The legal framework matters here. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for specific patients based on individual prescriptions [10]. Rhode Island also requires compounding pharmacies to hold an active Rhode Island Board of Pharmacy compounding license. Patients should verify licensure through the Rhode Island Department of Health provider directory before ordering.

Compounded dutasteride is not FDA-approved. The FDA's guidance on compounding states clearly that compounded drugs lack the safety and efficacy review of approved drugs [11]. That does not make them illegal, but it does mean patients and prescribers carry more responsibility for verifying pharmacy quality. Legitimate 503A pharmacies follow United States Pharmacopeia (USP) Chapter 795 standards for non-sterile compounding and should provide a certificate of analysis on request.

Off-label compounded formulations sometimes combine dutasteride with minoxidil in a topical preparation for androgenetic alopecia. Published data on topical dutasteride remain limited compared with oral use, though a randomized trial in the Journal of the American Academy of Dermatology demonstrated statistically significant improvements in hair density with oral dutasteride 0.5 mg versus placebo (P<0.001) [7]. Topical compounded formulations lack that level of evidence, and prescribers should document the clinical rationale.

Can You Get Dutasteride via Telehealth in Rhode Island?

Telehealth prescribing of dutasteride is legal in Rhode Island. State law permits licensed physicians and advanced practice providers to prescribe Schedule-exempt medications like dutasteride following a telehealth evaluation, provided the encounter meets the standard of care for an in-person visit [12].

Rhode Island adopted permanent telehealth parity rules after the COVID-19 public health emergency, and the Rhode Island Department of Health's telehealth guidance confirms that prescribing non-controlled medications via synchronous audio-video encounters is fully authorized [12]. Dutasteride is not a controlled substance, so there are no DEA Ryan Haight Act restrictions that would require an in-person visit.

A typical telehealth workflow for BPH or hair loss goes like this: the patient completes an intake questionnaire, uploads recent labs (PSA for BPH; no mandatory labs for hair loss), and joins a video visit. The clinician reviews history, conducts a virtual symptom assessment, and issues a prescription electronically to any licensed Rhode Island pharmacy. Total time from registration to prescription is often under 30 minutes.

The NEJM published data showing that telehealth encounters for chronic medication management produce comparable adherence outcomes to in-person visits for stable conditions [13]. Dutasteride's once-daily oral dosing and its established safety profile over more than two decades of post-market surveillance make it well-suited to telehealth-based prescribing.

One practical note: PSA testing before starting dutasteride for BPH is standard practice under AUA guidelines [6]. Telehealth providers should order a baseline PSA through a local Rhode Island lab before or at the time of prescribing. Dutasteride suppresses PSA by approximately 50% after six months, which the FDA label explicitly warns clinicians to account for when interpreting future PSA results [2].

How Dutasteride Works and Why Dose Matters

Dutasteride 0.5 mg once daily is the only FDA-approved dose for BPH, and it is the dose studied in essentially all major clinical trials [2]. The drug inhibits both type 1 and type 2 5-alpha reductase isoenzymes, compared with finasteride, which inhibits only type 2. That dual inhibition produces deeper DHT suppression.

The REDUCE trial (N=8,231) examined dutasteride 0.5 mg over four years and found a 23% relative risk reduction in BPH-related acute urinary retention or BPH-related surgery versus placebo [14]. The COMBAT trial (N=4,844) showed that combination therapy with dutasteride plus tamsulosin reduced symptom scores more than either drug alone over 24 months [15]. Both trials enrolled men with prostate volumes of at least 30 mL and PSA between 1.5 and 10 ng/mL, matching the AUA guideline thresholds.

For hair loss, Eun et al. (2010, N=153) compared dutasteride 0.5 mg, 2.5 mg, and finasteride 1 mg over 24 weeks. Dutasteride 0.5 mg produced greater improvement in target area hair count than finasteride 1 mg (P<0.05) [7]. Doses above 0.5 mg did not add meaningful benefit and are not used in standard practice.

The drug's half-life is approximately five weeks, which means steady-state DHT suppression takes several months to establish. Patients stopping the drug should expect DHT levels to normalize over a similar timeframe.

Rhode Island Savings Programs and Discount Strategies

The following decision framework organizes cost-reduction options by patient type in Rhode Island for 2026.

Patient with commercial insurance: Confirm generic dutasteride is on formulary. If on a high-deductible plan, compare the cash price with discount card against the deductible-applied cost. Use GoodRx, RxSaver, or the pharmacy's own savings program. Target price: $18 to $25 per month.

Patient with Rhode Island Medicaid: Submit PA documentation referencing AUA guideline criteria (prostate volume >30 mL or PSA >1.5 ng/mL) [6]. If denied, file a grievance within 90 days. Approved patients pay $0 to $3.65 per fill (standard RI Medicaid copay for generics).

Uninsured patient: Generic dutasteride is the default. Discount card programs including GoodRx, SingleCare, and Blink Health are accepted at major Rhode Island chains including CVS, Walgreens, Rite Aid, and Walmart Pharmacy. Prices at participating pharmacies range from $18 to $35 for a 30-day supply.

Patient interested in compounding: Verify the 503A pharmacy holds an active Rhode Island compounding license via the Rhode Island Department of Health online directory. Expect to pay approximately $40 per month. Compounded options may be appropriate for dose customization or when the prescriber has documented a specific clinical reason the commercial product is inadequate [10].

Patient using GSK manufacturer savings: GSK offers a savings card for Avodart brand that may reduce cost for commercially insured patients who specifically require the brand. The program is not available to patients using federal or state government insurance including Medicare and Medicaid, per federal anti-kickback statute requirements [16]. Rhode Island patients on Medicare Part D should review their plan's formulary during Open Enrollment, as Tier placement varies by plan.

The cheapest total pathway for most Rhode Island patients is generic dutasteride with a discount card at a warehouse pharmacy, often reaching $18 per month or less.

Safety Profile and Monitoring Requirements

Dutasteride carries an FDA-required warning regarding the risk of high-grade prostate cancer observed in the REDUCE trial [2]. The trial found a small but statistically significant increase in Gleason score 8 to 10 prostate cancers in the dutasteride arm (1.0% vs. 0.5%, P<0.001) [14]. The FDA label requires that this risk be discussed with patients before prescribing for BPH [2].

The drug is Category X for pregnancy exposure via skin absorption. Capsules should not be handled by women who are pregnant or may become pregnant. GSK's prescribing information states: "Women who are pregnant or may be pregnant should not handle dutasteride capsules" [2]. Rhode Island pharmacies are required to dispense dutasteride in childproof containers with appropriate labeling.

Common adverse effects include decreased libido (occurring in approximately 3% to 5% of patients in controlled trials), erectile dysfunction, ejaculation disorders, and gynecomastia [2]. These effects are generally reversible after discontinuation, given the drug's five-week half-life.

Annual PSA monitoring is appropriate for patients on long-term therapy. Because dutasteride suppresses PSA by roughly 50%, any PSA value measured on therapy should be doubled for comparison against age-specific reference ranges. Clinicians managing Rhode Island patients should document this adjustment in the chart. The AUA guideline states: "In patients on 5-ARI therapy, a PSA value rising from nadir should prompt evaluation for prostate cancer regardless of the absolute PSA level" [6].

Sexual side effects should be discussed at each follow-up. Post-finasteride syndrome, a condition involving persistent sexual and neuropsychiatric symptoms after stopping the drug, has been reported with 5-alpha reductase inhibitors, though causality remains debated in the literature [17]. Patients reporting persistent symptoms after discontinuation should be referred to a urologist or endocrinologist.

Comparing Dutasteride with Finasteride in Rhode Island

Finasteride 1 mg (Propecia) for hair loss and finasteride 5 mg (Proscar) for BPH are the main alternatives. Finasteride's generic cash price in Rhode Island averages $10 to $15 per month, lower than dutasteride [18]. Both drugs require a prescription.

The pharmacological difference is meaningful. Finasteride inhibits only type 2 5-alpha reductase, suppressing DHT by about 70%. Dutasteride's dual inhibition suppresses DHT by up to 90% [1]. Whether that additional suppression translates to better clinical outcomes depends on the indication.

For BPH, the COMBAT and REDUCE trials support dutasteride's efficacy, and the AUA does not designate either drug as superior for symptom control [6]. For hair loss, Eun et al. found dutasteride 0.5 mg superior to finasteride 1 mg on target area hair count at 24 weeks (P<0.05) [7]. A meta-analysis published in JAMA Dermatology confirmed that dutasteride produces numerically greater hair density improvements than finasteride across pooled randomized controlled trials [19].

Cost, side effect profile, and prescriber preference drive the choice in practice. Patients who have tried finasteride and experienced inadequate response for hair loss or BPH symptoms may find dutasteride a reasonable next step, provided the prescriber documents clinical rationale.

Patients should not take both drugs simultaneously. There is no evidence of additive benefit, and the combined antiandrogen burden increases side effect risk without a demonstrated therapeutic gain [2].

Rhode Island Telehealth Providers and Pharmacy Options

Rhode Island patients can access dutasteride prescriptions through national telehealth platforms that hold Rhode Island prescribing licenses, as well as through local urology, dermatology, and primary care offices. HealthRX providers licensed in Rhode Island can prescribe dutasteride following a complete telehealth evaluation that meets the Rhode Island Department of Health standard of care requirements [12].

For pharmacy fulfillment, all major chains operating in Rhode Island (CVS, Walgreens, Rite Aid) stock generic dutasteride. Independent pharmacies in Providence, Warwick, Cranston, and Pawtucket also carry the generic. Mail-order fulfillment through plan-affiliated mail pharmacies often provides 90-day supplies at reduced unit cost, typically $50 to $65 for a three-month supply versus $25 per month retail. That works out to a savings of $10 to $25 per quarter on the same medication.

Patients using BCBSRI or Tufts Health Plan should check whether their plan mandates mail-order for maintenance medications. Several commercial plans in Rhode Island require 90-day mail-order fills after the second retail fill for chronic medications. Dutasteride qualifies as a maintenance medication under most plan definitions after the first 90 days of therapy [8].